Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks

Quarfloxin

This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.

Quarfloxin is a first-in-class small-molecule targeted cancer therapeutic derived from the validated fluoroquinolone class of drugs. Quarfloxin was rationally designed to target a G-quadruplex (QPLX) DNA structure and disrupt protein-DNA interactions essential to cancer cells. The QPLX targeted by quarfloxin forms within ribosomal DNA (rDNA) and the QPLX is bound by the nucleolin protein.

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Quarfloxin Administered Intravenously Weekly for Three Weeks of a Four Week Cycle in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

C. Padgett

Carcinoma

Neuroendocrine Tumors

Carcinoma, Neuroendocrine

Carcinoid Tumor

Neoplasms, Glandular and Epithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Adenocarcinoma

Neuroendocrine Tumor

Neuroepithelioma

IV Quarfloxin 240 mg/m2 daily x5 days every 21 days

This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable hormones or other biochemical tumor markers.

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Claire Padgett, VP Clinical Operations

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas	NCT00955292	Advanced Solid ... Lymphoma	Quarfloxin	18 Years -	Cylene Pharmaceuticals
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	NCT00780663	Neuroendocrine ... Carcinoid Tumor	Quarfloxin	18 Years -	Cylene Pharmaceuticals
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	NCT00780663	Neuroendocrine ... Carcinoid Tumor	Quarfloxin	18 Years -	Cylene Pharmaceuticals
Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas	NCT00955292	Advanced Solid ... Lymphoma	Quarfloxin	18 Years -	Cylene Pharmaceuticals

Spots Global Cancer Trial Database for quarfloxin

Every month we try and update this database with for quarfloxin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for quarfloxin

Every month we try and update this database with for quarfloxin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for quarfloxin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.